Medication-Assisted Treatment (MAT) for Opioid Addiction

For decades, the standard advice for opioid addiction was to “get clean” and white-knuckle through withdrawal. We now know that approach fails most people - and that there is a better one. Medication-assisted treatment, or MAT, pairs an FDA-approved medication with counseling and support to treat opioid use disorder the way it actually behaves: as a chronic brain condition, not a lack of willpower. It is the most effective care we have, and the evidence on that point is not close. People who stay on these medications are less likely to die or to overdose than people who don’t.

What “medication-assisted treatment” actually means

MAT is sometimes called MOUD - medications for opioid use disorder. The newer term is more precise, because the medication isn’t a side dish that “assists” the real treatment. For many people it is the foundation, with counseling and other support built around it.

The idea is straightforward. Long-term opioid use rewires the brain’s reward and stress systems, so stopping triggers intense cravings and withdrawal that pull a person back to use. MAT medications act on the same opioid receptors involved in that process - either calming the system down or blocking it - so a person can stabilize, think clearly, hold a job, and do the harder work of recovery without being ruled by cravings.

There are three FDA-approved medications. They work in very different ways, and the right one depends on the person.

The three medications, and how they work

According to the National Institute on Drug Abuse (NIDA), each medication targets the brain’s mu-opioid receptors, but the resemblance ends there.

Methadone is a full opioid agonist. It binds to and activates the same receptors that heroin and fentanyl do - but slowly, and steadily, so it eases withdrawal and cravings without producing the highs and crashes of misuse. Because it is a long-acting opioid, methadone for addiction can only be dispensed through a SAMHSA-certified opioid treatment program (often called a methadone clinic), where people initially come in regularly for their dose.

Buprenorphine is a partial agonist. It activates the same receptors, but only to a limited degree - enough to quiet withdrawal and cravings, while blunting or blocking the effect of other opioids on top of it. That partial action gives it a “ceiling,” which lowers the risk of overdose compared with a full agonist. Buprenorphine was the first OUD medication that could be prescribed in a regular doctor’s office, which dramatically widened access. It is often combined with naloxone (the brand many people know is Suboxone) to discourage misuse.

Naltrexone is the outlier. It is an antagonist - it doesn’t activate anything. It simply sits on the opioid receptors and blocks them, so opioids can’t produce pleasure or relief while it’s on board. The long-acting injectable form (Vivitrol) lasts about a month. The catch: a person has to be fully through withdrawal - generally 7 to 10 days opioid-free - before starting it, or it can trigger sudden, severe withdrawal.

No single medication is “best.” Methadone and buprenorphine are equally effective for many people at reducing opioid use and keeping them in treatment; naltrexone is an option for someone who has already detoxed or who prefers a non-opioid medication. Matching the medication to the person is the whole point.

Why MAT works when willpower alone often doesn’t

Here is the part that surprises people: these medications don’t just make withdrawal more bearable. They change survival odds.

The Centers for Disease Control and Prevention (CDC) states plainly that medication treatment of opioid use disorder is “associated with reduced risk for overdose and overall mortality.” Studies of methadone and buprenorphine consistently show large drops in opioid overdose deaths among people who stay on treatment. The medications also reduce the risky behaviors - like sharing needles - that spread HIV and hepatitis C.

Compare that with detox alone. Going through withdrawal without follow-up medication is not only less effective - it can be more dangerous. The CDC notes that detoxification on its own “is not recommended” for opioid use disorder, because once a person’s tolerance drops, a return to their old amount can be fatal. Many overdose deaths happen in exactly that window, after a period of abstinence. Staying on medication keeps tolerance and cravings stable and removes that cliff.

This is why clinicians increasingly treat opioid use disorder like any other chronic illness. We don’t ask people with diabetes to manage on motivation alone. Addiction medicine has reached the same conclusion.

If you or someone you love is struggling with opioids, call or text 988 (US) anytime, or contact SAMHSA’s National Helpline at 1-800-662-HELP (4357) - free, confidential, 24/7 treatment referrals in English and Spanish.

Medication is the foundation, not the whole house

MAT works best as part of a “whole-patient” approach. Alongside the medication, most programs offer counseling, behavioral therapy, and connection to peer support and recovery services. The medication handles the biology - the cravings and withdrawal that hijack decision-making - so a person has the stability to address the rest: the reasons use started, the mental-health conditions that often travel with it, housing, relationships, and rebuilding a life.

How long someone stays on medication varies. There is no fixed finish line, and there’s no medical reason to rush off. For many people, treatment continues for years; some stay on it indefinitely, the way someone might stay on blood-pressure medication. Stopping is a decision to make slowly, with a clinician, when life is stable - not a goal to chase prematurely.

One of the most stubborn barriers is stigma. People are sometimes told that being on methadone or buprenorphine means they’re “not really sober” or have “traded one drug for another.” That framing isn’t supported by the science. These medications, taken as prescribed, don’t produce a high; they restore normal function. Believing otherwise has kept people away from the single most effective treatment available - and it has cost lives.

What’s changed: easier access to treatment

For years, a federal rule (the “X-waiver”) required doctors to get a special waiver and accept patient limits before they could prescribe buprenorphine. That bottleneck kept the medication out of reach for many.

That changed. The Consolidated Appropriations Act of 2023, signed into law on December 29, 2022, eliminated the DATA-Waiver Program. Now any clinician with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine for opioid use disorder, with no patient cap, where state law allows. It’s now possible to start treatment through a primary-care doctor, many telehealth services, and a growing number of clinics - not only specialty programs.

How to start

The first step is a conversation with a clinician - a primary-care doctor, an addiction-medicine specialist, or an opioid treatment program. They’ll assess the situation, talk through which medication fits, and explain what to expect. You do not have to be at “rock bottom,” and you do not have to have failed other approaches first. Earlier is better.

If you don’t know where to begin, SAMHSA’s National Helpline (1-800-662-HELP) and its online treatment locator can connect you to programs nearby. The call is free and confidential.

Know the signs of an opioid overdose

Anyone affected by opioids - including a person in treatment and the people around them - should know how to recognize and respond to an overdose. Signs include unresponsiveness (not waking to a loud voice or a firm rub on the chest), slow or stopped breathing, and very small “pinpoint” pupils.

If you suspect an overdose, call 911 immediately, give naloxone if it’s available, and stay with the person - lay them on their side and keep them breathing until help arrives. Naloxone reverses an opioid overdose within minutes, is safe, and can be carried and used by anyone. Keeping it on hand is one of the simplest ways to prevent a death.

FAQ

Is MAT just replacing one addiction with another? No. Addiction is compulsive use that continues despite harm. Taking a prescribed, steady dose of methadone or buprenorphine that restores normal function - without a high - is treatment, not addiction. Major health authorities, including NIDA and the CDC, consider these medications the standard of care for opioid use disorder.

How long does someone stay on the medication? There’s no set timeline. Some people take it for months, many for years, and some indefinitely. Because the risk of return to use and overdose rises after stopping, the decision to taper off is made gradually with a clinician, when a person is stable - never rushed.

Do I need counseling too, or is the medication enough? The medication is the most important part, and it helps even on its own. But MAT is designed as a whole-patient approach. Counseling and support address the issues behind the addiction and strengthen long-term recovery, so most programs offer both.

Where do I get methadone versus buprenorphine? Methadone for opioid use disorder is dispensed only through SAMHSA-certified opioid treatment programs. Buprenorphine can be prescribed by many regular clinicians and through telehealth. Naltrexone, a non-opioid option, can also be started after a person has fully withdrawn from opioids.

Sources

• National Institute on Drug Abuse (NIDA) - Medications for Opioid Use Disorder
• Centers for Disease Control and Prevention (CDC) - Treating Opioid Use Disorder and Reversing an Opioid Overdose
• Substance Abuse and Mental Health Services Administration (SAMHSA) - Waiver Elimination (MAT Act) and National Helpline
• MedlinePlus - Opioid Overdose